DBV Technologies (NASDAQ:DBVT) Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded DBV Technologies from "sell" to "hold," while other analysts issued mostly positive notes (Citizens JMP, Citigroup, Guggenheim) and the consensus rating is a Moderate Buy with an average target price of $40.25.
• The stock is volatile and loss-making—shares fell about 5.4% to open at $19.87, with a 12‑month range of $7.53–$26.18, a market cap of $1.11B and recent quarterly EPS of –$1.15 alongside deeply negative margins and ROE.
• Institutions own 71.74% of the company after large fourth‑quarter purchases by firms like Artisan Partners, Vivo Capital and Siren, while DBV remains a clinical‑stage biopharma developing the Viaskin platform, notably the lead candidate Viaskin Peanut.

DBV Technologies (NASDAQ:DBVT - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

A number of other analysts have also recently commented on DBVT. Citizens Jmp upped their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research report on Friday. Finally, Guggenheim reaffirmed a "buy" rating and set a $51.00 price target on shares of DBV Technologies in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $40.25.

DBV Technologies Stock Down 5.4%

Shares of DBV Technologies stock opened at $19.87 on Friday. DBV Technologies has a twelve month low of $7.53 and a twelve month high of $26.18. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -3.81 and a beta of -0.97. The company's fifty day moving average is $20.89 and its 200 day moving average is $18.85.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($1.15) earnings per share for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The business had revenue of $0.65 million during the quarter. As a group, equities analysts anticipate that DBV Technologies will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A number of institutional investors have recently bought and sold shares of DBVT. Artisan Partners Limited Partnership raised its holdings in shares of DBV Technologies by 6,273.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company's stock valued at $63,435,000 after purchasing an additional 3,257,135 shares during the period. Siren L.L.C. acquired a new position in shares of DBV Technologies during the fourth quarter valued at about $35,606,000. Vivo Capital LLC raised its holdings in shares of DBV Technologies by 133.4% during the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company's stock valued at $47,189,000 after purchasing an additional 1,407,120 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of DBV Technologies during the second quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC acquired a new position in shares of DBV Technologies during the second quarter valued at about $9,649,000. Institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.